SCHEMBL6465726

SCHEMBL6465726

COc1cccc2c(C)nc(Nc3nc(O)c4ccccc4n3)nc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
ALDH1A1 P00352 2/20 0.50
MEN1 O00255 2/20 0.50
NPC1 O15118 1/20 0.50
TP53 P04637 1/20 0.50
MAPT P10636 1/20 0.50
MAPK1 P28482 1/20 0.50
RAB9A P51151 1/20 0.50
KDM1A O60341 1/20 0.44
RAD52 P43351 2/20 0.42
USP2 O75604 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
POLB P06746 2/20 0.42
KDM4E B2RXH2 2/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TOP2A P11388 1/20 0.41
TOP2B Q02880 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6465587 0.87 ADORA2B (0.49) KMT2ASMN1; SMN2ALDH1A1MEN1NPC1
SCHEMBL6470559 0.86 POLB (0.51) KMT2ASMN1; SMN2ALDH1A1POLBKDM4E
SCHEMBL6469244 0.85 TDP2 (0.48) KMT2ASMN1; SMN2ALDH1A1MEN1NPC1
SCHEMBL6470113 0.84 MAPT (0.51) KMT2ASMN1; SMN2ALDH1A1MEN1NPC1
SCHEMBL6469519 0.84 TP53 (0.41) KMT2ASMN1; SMN2ALDH1A1MEN1NPC1
SCHEMBL6467861 0.82 POLB (0.42) KMT2ASMN1; SMN2ALDH1A1MEN1TP53
SCHEMBL9921194 0.82 KDM4E (0.48) KMT2ASMN1; SMN2ALDH1A1MEN1NPC1
SCHEMBL6469112 0.81 JUND (0.43) KMT2ASMN1; SMN2ALDH1A1MEN1NPC1
Trifluoroacetic Acid SCHEMBL6468039 0.80 PAX8 (0.40) KMT2ASMN1; SMN2ALDH1A1POLBKDM4E
Trifluoroacetic Acid SCHEMBL6469512 0.80 KMT2A (0.43) KMT2ASMN1; SMN2ALDH1A1MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB KMT2A 2156/4885SMN1; SMN2 4360/4885ALDH1A1 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.